Autolus Therapeutics (AUTL) Non Operating Income (2017 - 2025)
Autolus Therapeutics posted quarterly Non Operating Income of -$3.5 million for Q4 2025, down 115.91% year-on-year from $22.1 million in Q4 2024, and down 4292.86% on a QoQ basis from $84000.0 in Q3 2025.
Autolus Therapeutics (AUTL) has 9 years of Non Operating Income data on file, last reported at -$3.5 million in Q4 2025.
- For the quarter ending Q4 2025, Non Operating Income fell 115.91% year-over-year to -$3.5 million; the trailing twelve-month figure through Dec 2025 stood at -$6.0 million (down 171.9% YoY), and the FY2025 full-year result was $515000.0, down 97.69% from the prior year.
- Non Operating Income for Q4 2025 stood at -$3.5 million, down from $84000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $979.0 million in Q3 2021 and bottomed at -$23.9 million in Q4 2023.
- The 5-year median for Non Operating Income is -$488500.0 (2023), against an average of $47.4 million.
- The widest annual swing landed in 2021, when Non Operating Income surged 39703.56%; it then tumbled 10538.24% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$199000.0 in 2021, then sank by 374.87% to -$945000.0 in 2022, then tumbled by 2431.64% to -$23.9 million in 2023, then surged by 192.51% to $22.1 million in 2024, then sank by 115.91% to -$3.5 million in 2025.
- The last three Non Operating Income figures came in at -$3.5 million (Q4 2025), $84000.0 (Q3 2025), and $135000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 201.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | -3.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.52 Mn |
| Sep 30, 2025 | 84,000.00 |
| Jun 30, 2025 | 135,000.00 |
| Mar 31, 2025 | -2.70 Mn |
| Dec 31, 2024 | 22.13 Mn |
| Sep 30, 2024 | -14.20 Mn |
| Jun 30, 2024 | 708,000.00 |
| Mar 31, 2024 | -300,000.00 |
| Dec 31, 2023 | -23.92 Mn |
| Sep 30, 2023 | 136,000.00 |
| Jun 30, 2023 | -1.14 Mn |
| Mar 31, 2023 | -677,000.00 |
| Dec 31, 2022 | -945,000.00 |
| Sep 30, 2022 | -5.43 Mn |
| Jun 30, 2022 | -1.33 Mn |
| Mar 31, 2022 | 860,000.00 |
| Dec 31, 2021 | -199,000.00 |
| Sep 30, 2021 | 979.00 Mn |
| Jun 30, 2021 | -1.81 Mn |
| Mar 31, 2021 | 882,000.00 |
| Dec 31, 2020 | -1.65 Mn |
| Sep 30, 2020 | -2.47 Mn |
| Jun 30, 2020 | 478,000.00 |
| Mar 31, 2020 | 4.99 Mn |
| Jun 30, 2019 | 5.45 Mn |
| Mar 31, 2019 | -443,000.00 |
| Sep 30, 2018 | 2.00 Mn |
| Jun 30, 2018 | 6.66 Mn |
| Mar 31, 2018 | -2.65 Mn |
| Dec 31, 2017 | -685,000.00 |